SCHEMBL6624382

SCHEMBL6624382

Cc1cc(Cl)cc(Cl)c1S(=O)(=O)Nc1ccsc1CCN1CCOCC1=O

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.37
EPHX2 P34913 1/20 0.37
TP53 P04637 2/20 0.33
MAPT P10636 3/20 0.32
APLNR P35414 1/20 0.32
POLB P06746 1/20 0.32
CNR2 P34972 1/20 0.32
ALDH1A1 P00352 2/20 0.32
NMT1 P30419 1/20 0.32
PFKFB3 Q16875 1/20 0.32
TSHR P16473 1/20 0.32
MEN1 O00255 1/20 0.31
LMNA P02545 1/20 0.31
HTT P42858 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6624148 0.94 HSD11B1 (0.42) HSD11B1EPHX2TP53MAPTAPLNR
SCHEMBL6624772 0.86 HSD11B1 (0.42) HSD11B1MAPTALDH1A1NMT1TSHR
SCHEMBL6623850 0.85 MAPT (0.38) HSD11B1EPHX2TP53MAPTPOLB
SCHEMBL6628472 0.83 HSD11B1 (0.38) HSD11B1EPHX2TP53MAPTPOLB
SCHEMBL3621175 0.82 HSD11B1 (0.54) HSD11B1EPHX2MAPTPOLBCNR2
SCHEMBL6623901 0.81 HSD11B1 (0.43) HSD11B1TP53ALDH1A1
SCHEMBL6627716 0.81 PTGES2 (0.39) EPHX2TP53MAPTALDH1A1MEN1
SCHEMBL6629251 0.79 HSD11B1 (0.47) HSD11B1MAPTCNR2ALDH1A1NMT1
SCHEMBL5830665 0.79 HSD11B1 (0.39) HSD11B1EPHX2APLNRPOLBALDH1A1
SCHEMBL5831444 0.79 HSD11B1 (0.41) HSD11B1EPHX2MAPTNMT1PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO claimed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
WO-2019075394-A1 COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME VANDERKLISH PETER (US) 2019-04-18 WO disclosed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
EP-1461333-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed
WO-2003044009-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885EPHX2 611/4885TP53 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.